Neoadjuvant systemic therapy in stage III and IV resectable melanoma: an update to management and future directions
New Zealand Medical Journal · 17.04.2026 · 139 (1633) · 93-99
DOI: 10.26635/6965.7104 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift New Zealand Medical Journal, online erschienen am 17.04.2026. Verfasst von Samuel Reddish und 4 weiteren Autor:innen. Beteiligte Einrichtung: Resident Medical Officer, Health New Zealand - Te Whatu Ora Waitematā. Hauptthemen laut MEDLINE: Melanoma, Neoadjuvant Therapy, Skin Neoplasms.
Abstract (Originalsprache)
aim: This article aims to review the role of neoadjuvant systemic therapy (NAST) in the management of clinical stage III or IV resectable melanoma. The review focusses on the evidence behind neoadjuvant systemic therapies and on developing a protocol for widespread implementation within the New Zealand health system. We outline suggested future directions for this evolving treatment. methods: A detailed literature review was conducted, examining the rationale, mechanisms of action and recent clinical trial data supporting the use of NAST in melanoma management. results: NAST provides notable immunological advantages by harnessing tumour antigen presence in situ, enhancing immune response and improving event-free survival (EFS) rates. Recent randomised phase II and III controlled trials have demonstrated significant improvements in EFS rates with NAST compared to standard adjuvant therapy alone. The SWOG-S1801 trial reported a 2-year EFS rate of 72% with neoadjuvant–adjuvant pembrolizumab compared to 49% for adjuvant-only therapy. The NADINA trial found a remarkable increase in 1-year EFS with neoadjuvant ipilimumab and nivolumab (83.7%) compared to adjuvant nivolumab alone (57.2%). conclusion: Current evidence strongly supports incorporating NAST into standard clinical practice for resectable clinical stage III and IV melanoma, promising substantial improvements in patient outcomes with acceptable safety profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Resident Medical Officer, Health New Zealand - Te Whatu Ora Waitematā.
- Resident Medical Officer, RACP Trainee, Health New Zealand - Te Whatu Ora Counties Manukau.
- Medical Oncologist, Health New Zealand - Te Whatu Ora Te Toka Tumai Auckland.
- Surgical Oncologist and Melanoma Specialist, Health New Zealand - Te Whatu Ora Waitematā.
- General Surgeon and Surgical Oncologist, Health New Zealand - Te Whatu Ora Waitematā.
Zitieren
APA
Reddish, S., Seol, S., Rivalland, G., Martin, R. C., & Russell, M. (2026). Neoadjuvant systemic therapy in stage III and IV resectable melanoma: an update to management and future directions. New Zealand Medical Journal, 139(1633), 93-99. https://doi.org/10.26635/6965.7104
Vancouver
Reddish S, Seol S, Rivalland G, Martin RC, Russell M. Neoadjuvant systemic therapy in stage III and IV resectable melanoma: an update to management and future directions. New Zealand Medical Journal. 2026;139(1633):93-99. doi:10.26635/6965.7104
BibTeX
@article{Reddish2026,
author = {Reddish, Samuel and Seol, Sarah and Rivalland, Gareth and Martin, Richard Cw and Russell, Michael},
title = {Neoadjuvant systemic therapy in stage III and IV resectable melanoma: an update to management and future directions},
journal = {New Zealand Medical Journal},
year = {2026},
volume = {139},
number = {1633},
pages = {93--99},
doi = {10.26635/6965.7104}
}
EUVIMED